Evidence overview
Curcumin
Curcumin is the principal active compound in turmeric and is studied across the same broad range of indications, but typically at standardized higher curcuminoid concentrations than whole-turmeric supplements provide. The evidence base spans osteoarthritis, inflammatory markers, metabolic conditions, and mood. The defining practical question for curcumin specifically is which absorption-enhanced formulation to use, since standard curcumin has very limited oral bioavailability.
Most studied for
Coverage pending
PubMed coverage
Coverage pending
Safety profile
In your full report
Mechanism class
The principal active compound in turmeric, a polyphenolic diarylheptanoid. Modulates inflammatory pathways (NF-kB, COX-2,...
Study coverage
Study coverage by goal
PubMed counts for Curcumin grouped by the goal each study targets.
Evidence overview is temporarily unavailable for Curcumin.
Evidence
What the evidence covers
The terrain of the published literature, not its conclusions.
Curcumin is the principal active compound in turmeric (Curcuma longa) and is studied across the same indications as turmeric extracts but at standardized higher curcuminoid concentrations. The clinical literature spans osteoarthritis (where the supplement has umbrella-meta-analysis-level evidence for symptomatic benefit), inflammatory and antioxidant biomarkers, lipid profiles, type 2 diabetes-related markers, depression and other mood conditions, ulcerative colitis, and many smaller research areas. Curcumin's mechanisms span inflammation (NF-kB, COX-2 modulation), antioxidant activity, and effects on multiple cellular signaling pathways - which is the conceptual basis for its unusually broad indication base.
The outcome dimensions covered most heavily are osteoarthritis (the most-asked consumer use, where umbrella meta-analyses synthesize multiple individual trials), inflammatory and antioxidant biomarkers (the mechanistic foundation underlying most claimed benefits), lipid profile improvements (consistent across many trials), metabolic markers in type 2 diabetes and metabolic syndrome, and mood including depression. The 2024 comprehensive synthesis across 103 RCTs and 42 health outcomes is the closest the field has to a supplement-overall reference document.
Demographically, the literature is unusually broad across populations and conditions, reflecting curcumin's pleiotropic mechanism. The single most-practical question for curcumin specifically is bioavailability: standard curcumin has very poor oral absorption (less than 1% in some assays), which is why nearly all modern supplemental products use one of several absorption-enhancement strategies: piperine co-administration (most common, lowest cost), phospholipid complexes (Meriva), micellar formulations, gamma-cyclodextrin complexes, or nanoparticle delivery (Theracurmin, Longvida). Trial results depend substantially on which formulation was used, with bioavailability differences of 5-30x reported between products.
Safety
Safety summary
Common adverse events, drug interactions, and special populations.
Curcumin is generally well-tolerated at typical supplemental doses. The most-common adverse effects are gastrointestinal: nausea, abdominal discomfort, and diarrhea at higher doses. Concerns have been raised about rare cases of drug-induced liver injury associated with concentrated curcumin supplements, particularly absorption-enhanced formulations; pharmacovigilance reports document a trend that warrants awareness, though absolute risk appears low. Drug interactions include theoretical additive effects with anticoagulants (curcumin affects platelet function), reduced absorption of iron and zinc, and a debated interaction with chemotherapy agents in oncology contexts. People with gallstones, on anticoagulants, or undergoing chemotherapy should consult a clinician.
This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.
Foundations
Foundation of the evidence base
A few studies the field anchors on. Not the full picture, just the starting points.
Comprehensive systematic review covering 103 RCTs across 42 health outcomes, the field's most-thorough supplement-overall reference for curcumin/turmeric.
View on PubMedGRADE-assessed meta-analysis on the antioxidant and anti-inflammatory mechanisms underpinning most claimed health benefits. The methodological reference for curcumin's mechanistic claims.
View on PubMedUmbrella meta-analysis specifically on curcumin for osteoarthritis - the supplement's most-asked clinical application. Top-of-pyramid evidence summary for this primary indication.
View on PubMed
Limitations
What this page doesn't answer
Where the public summary stops and the personalized report begins.
This page summarizes the curcumin literature at a general level. It does not address which absorption-enhanced formulation (piperine-co-administered, Meriva, BCM-95, Theracurmin, Longvida, etc.) is right for your specific goal, what equivalent dose to use given the chosen formulation (formulations vary by 5-30x in bioavailability), how curcumin interacts with the medications you take, or whether turmeric (whole-rhizome) vs. curcumin (isolated) suits your situation. Formulation selection is the single most-consequential variable in this supplement's evidence base.
Personalized to you
Get a personalized Curcumin report
Your free first report adds the things this page doesn't: per-goal evidence breakdown, demographic-specific findings, full citation list, and a safety section tailored to your profile.
Free first report. No credit card. Cancel anytime.
Get notified when new evidence appears
We'll email you when the literature on Curcumin materially updates. No account required.